Market research
B9A.F BioArctic AB (publ)
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 247.09
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.65
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- SE0010323311
- Market cap
- 2B
- P/E ratio
- 247.09
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.65
About
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatment; lecanemab, which is in Phase 3 clinical trials for presymptomatic treatment; exidavnemab, which is in Phase 2 clinical trials; lecanemab back-up, BAN2803, ND3014, and BAN2802, which are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, and PD-BT2238, which are in the research stage. The company has a research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule, and with Mesenkia Therapeutics to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Research context
BioArctic AB (publ) appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the B9A.F discussion.
5 years, 7 months ago
BioArctic AB (publ) is currently in a long term uptrend where the price is trading 53.9% above its 200 day moving average.
From a valuation standpoint, the stock is 90.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 129.1.
BioArctic AB (publ)'s total revenue sank by 68.4% to $8M since the same quarter in the previous year.
Its net income has increased by 22.8% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.9% to $-34M since the same quarter in the previous year.
Based on the above factors, BioArctic AB (publ) gets an overall score of 4/5.